The Patent Finder

Universite Paris-Saclay

146 patents currently held · Updated Nov 18, 2026
36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 7 name spellings.

7
Ending by 2030
Jan 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 18 to 27, 2026 · next Dec 18
  • 2 fees due Jan 7 to 21, 2027 · next Jan 7
  • 1 fee due Feb 27, 2027
    The maintenance fee for Microfluidic Analysis Device and Method (US 10,393,699) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
  • 2 fees due Apr 1 to 8, 2027 · next Apr 1
  • 2 fees due May 12 to 28, 2027 · next May 12
  • 2 fees due Jul 5 to 28, 2027 · next Jul 5
  • 2 fees due Aug 25 to 27, 2027 · next Aug 25
  • 4 fees due Sep 10 to 29, 2027 · next Sep 10
  • 4 fees due Oct 2 to 26, 2027 · next Oct 2
  • 5 fees due Nov 3 to 17, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

  • 9 of the patents on this record were granted since Aug 20, 2026
  • 3 terms have ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,704,972Gemcitabine Derivatives Nanoparticles
In force
 · High confidence
In forceHigh confidence
US 8,232,518Device and Method for Characterizing Surfaces
In force
 · High confidence
In forceHigh confidence
US 8,178,657Polypeptide Sequence Involved in the Modulation of the Immunosuppresive Effect of Viral Proteins
In force
 · High confidence
In forceHigh confidence
US 11,203,788TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms
In force
 · High confidence
In forceHigh confidence
US 10,662,482TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms
In force
 · High confidence
In forceHigh confidence
US 8,934,593Very High Precision Device for Measuring the Time a Signal is Input
In force
 · High confidence
In forceHigh confidence
US 9,297,046TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms
In force
 · High confidence
In forceHigh confidence
US 9,327,961Electrodynamic speaker structure having MEMS technology
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,228,962Adjustable Cathodoluminescence Detection System and Microscope Employing Such a System
In force
 · Medium confidence
In forceMedium confidence
US 9,389,233TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms
In force
 · High confidence
In forceHigh confidence
10 of 146 patents shown.
Pro members see all 146.
Pro members: see all 146 patents
Also on record, not counted in the 146: 36 patents in force now held by others · 37 lapsed for an unpaid fee · 13 ended at full term · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

67 pending · 30 abandoned · 6 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited